

Turkey Biosimilar Market Size, Share, Trends and Forecast by Molecule, Indication, Manufacturing Type, and Region, 2026-2034

<https://marketpublishers.com/r/T1C48AF44594EN.html>

Date: August 2026

Pages: 120

Price: US\$ 2,999.00 (Single User License)

ID: T1C48AF44594EN

Abstracts

The Turkey biosimilar market size reached USD 422.0 Million in 2025. The market is projected to reach USD 2,711.7 Million by 2034, exhibiting a growth rate (CAGR) of 22.27% during 2026-2034. The market is expanding as demand grows for affordable treatments in therapeutic areas such as oncology and autoimmune diseases. Regional pharmaceuticals are shifting their focus to research, development, and sophisticated manufacturing to address increasing healthcare needs. Greater activity in clinical trials and collaborations is providing better product availability and quality. As businesses build up their strengths and diversify their portfolios, they are also targeting regional and international presence, which is further fueling the growth of the Turkey biosimilar market share.

TURKEY BIOSIMILAR MARKET TRENDS:

Regulatory Clarity Enhances Market Confidence

Turkey has made significant progress in shaping a more predictable regulatory path for biosimilars. In September 2024, the Turkish Medicines and Medical Devices Authority (T?TCK) introduced updates to its Guideline on Biosimilar Pharmaceuticals, offering greater clarity on data expectations, comparability protocols, and manufacturing adjustments. This update helps create a more transparent approval environment for biosimilar developers encouraging faster market entry and improved product consistency. With clearer regulatory signals, developers can more confidently allocate resources toward local registration and production efforts. The guideline aligns with global best practices, enhancing the Turkish biosimilar space more attractive for international collaboration and local investment. This regulatory progress is not just

about compliance; it's also about strengthening the industry's infrastructure to better serve long-term health system sustainability. As more products transition from development to approval under these enhanced rules, both access and competition are expected to increase. Overall, these refinements represent a critical step forward in reinforcing regulatory trust and accelerating Turkey biosimilar market growth.

Government Innovation Initiatives Fuel Momentum

Turkey is actively advancing its healthcare innovation agenda, and biosimilars are increasingly integrated into this strategy. Through national funding initiatives and supportive pricing frameworks, the country is creating a more accessible environment for biosimilar development. In March 2025, public agencies reinforced their commitment by expanding eligibility for state-backed R&D grants to include biosimilar projects, enabling academic and private-sector collaboration in early-stage development. This complements recent updates to pharmaceutical pricing policies, which aim to make biosimilar products more competitively positioned alongside originator biologics. Together, these measures are helping reduce barriers to entry while encouraging sustainable growth in domestic development. These changes also indicate a shift in policy focus from cost control alone to long-term capability building. By supporting biosimilar innovation both structurally and financially, Turkey is fostering an environment where market entry is more viable, and product diversity can flourish. This approach reflects a maturing ecosystem that recognizes the strategic importance of biosimilars in reducing healthcare costs and improving access. Such coordinated progress is emblematic of broader Turkey biosimilar market trends.

Strategic Expansion Through International Licensing

Turkey is strengthening its biosimilar ecosystem through strategic international licensing partnerships that support market entry and distribution. In January 2025, a licensing and commercialization agreement was signed, to introduce BAT2206, a biosimilar of ustekinumab (Stelara), into the Turkish market. Under the deal, World Medicine will manage registration, imports, and marketing in Turkey, while Bio?Thera will handle commercial supply and manufacturing from its facilities abroad. This collaboration smartly leverages external production capacity while ensuring that biosimilar access in Turkey is both timely and efficiently managed. It also reflects how licensing agreements are becoming a key tool for introducing advanced biological treatments without waiting for local manufacturing to catch up. As Turkey's healthcare sector continues to evolve, such collaborations help diversify the biosimilar pipeline and bring treatments to patients faster. The model supports access without compromising on quality or regulatory

alignment, delivering both flexibility and scale. This approach underscores the growing sophistication of the country's biosimilar strategy and reinforces its position in the regional healthcare landscape.

TURKEY BIOSIMILAR MARKET SEGMENTATION:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2026-2034. Our report has categorized the market based on molecule, indication, and manufacturing type.

Molecule Insights:

Infliximab

Insulin Glargine

Epoetin Alfa

Etanercept

Filgrastim

Somatropin

Rituximab

Follitropin Alfa

Adalimumab

Pegfilgrastim

Trastuzumab

Bevacizumab

Others

The report has provided a detailed breakup and analysis of the market based on the molecule. This includes infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, follitropin alfa, adalimumab, pegfilgrastim, trastuzumab, bevacizumab, and others.

Indication Insights:

Auto-Immune Diseases

Blood Disorder

Diabetes

Oncology

Growth Deficiency

Female Infertility

Others

A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes auto-immune diseases, blood disorders, diabetes, oncology, growth deficiency, female infertility, and others.

Manufacturing Type Insights:

In-house Manufacturing

Contract Manufacturing

The report has provided a detailed breakup and analysis of the market based on the manufacturing type. This includes in-house manufacturing and contract manufacturing.

Regional Insights:

Marmara

Central Anatolia

Mediterranean

Aegean

Southeastern Anatolia

Black Sea

Eastern Anatolia

The report has also provided a comprehensive analysis of all the major regional markets, which include Marmara, Central Anatolia, Mediterranean, Aegean, Southeastern Anatolia, Black Sea, and Eastern Anatolia.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT

How has the Turkey biosimilar market performed so far and how will it perform in the coming years?

What is the breakup of the Turkey biosimilar market on the basis of molecule?

What is the breakup of the Turkey biosimilar market on the basis of indication?

What is the breakup of the Turkey biosimilar market on the basis of manufacturing type?

What is the breakup of the Turkey biosimilar market on the basis of region?

What are the various stages in the value chain of the Turkey biosimilar market?

What are the key driving factors and challenges in the Turkey biosimilar market?

What is the structure of the Turkey biosimilar market and who are the key players?

What is the degree of competition in the Turkey biosimilar market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 TURKEY BIOSIMILAR MARKET - INTRODUCTION

- 4.1 Overview
- 4.2 Market Dynamics
- 4.3 Industry Trends
- 4.4 Competitive Intelligence

5 TURKEY BIOSIMILAR MARKET LANDSCAPE

- 5.1 Historical and Current Market Trends (2020-2025)
- 5.2 Market Forecast (2026-2034)

6 TURKEY BIOSIMILAR MARKET - BREAKUP BY MOLECULE

- 6.1 Infliximab
 - 6.1.1 Overview
 - 6.1.2 Historical and Current Market Trends (2020-2025)
 - 6.1.3 Market Forecast (2026-2034)
- 6.2 Insulin Glargine
 - 6.2.1 Overview
 - 6.2.2 Historical and Current Market Trends (2020-2025)

- 6.2.3 Market Forecast (2026-2034)
- 6.3 Epoetin Alfa
 - 6.3.1 Overview
 - 6.3.2 Historical and Current Market Trends (2020-2025)
 - 6.3.3 Market Forecast (2026-2034)
- 6.4 Etanercept
 - 6.4.1 Overview
 - 6.4.2 Historical and Current Market Trends (2020-2025)
 - 6.4.3 Market Forecast (2026-2034)
- 6.5 Filgrastim
 - 6.5.1 Overview
 - 6.5.2 Historical and Current Market Trends (2020-2025)
 - 6.5.3 Market Forecast (2026-2034)
- 6.6 Somatropin
 - 6.6.1 Overview
 - 6.6.2 Historical and Current Market Trends (2020-2025)
 - 6.6.3 Market Forecast (2026-2034)
- 6.7 Rituximab
 - 6.7.1 Overview
 - 6.7.2 Historical and Current Market Trends (2020-2025)
 - 6.7.3 Market Forecast (2026-2034)
- 6.8 Follitropin Alfa
 - 6.8.1 Overview
 - 6.8.2 Historical and Current Market Trends (2020-2025)
 - 6.8.3 Market Forecast (2026-2034)
- 6.9 Adalimumab
 - 6.9.1 Overview
 - 6.9.2 Historical and Current Market Trends (2020-2025)
 - 6.9.3 Market Forecast (2026-2034)
- 6.10 Pegfilgrastim
 - 6.10.1 Overview
 - 6.10.2 Historical and Current Market Trends (2020-2025)
 - 6.10.3 Market Forecast (2026-2034)
- 6.11 Trastuzumab
 - 6.11.1 Overview
 - 6.11.2 Historical and Current Market Trends (2020-2025)
 - 6.11.3 Market Forecast (2026-2034)
- 6.12 Bevacizumab
 - 6.12.1 Overview

6.12.2 Historical and Current Market Trends (2020-2025)

6.12.3 Market Forecast (2026-2034)

6.13 Others

6.13.1 Historical and Current Market Trends (2020-2025)

6.13.2 Market Forecast (2026-2034)

7 TURKEY BIOSIMILAR MARKET - BREAKUP BY INDICATION

7.1 Auto-Immune Diseases

7.1.1 Overview

7.1.2 Historical and Current Market Trends (2020-2025)

7.1.3 Market Forecast (2026-2034)

7.2 Blood Disorder

7.2.1 Overview

7.2.2 Historical and Current Market Trends (2020-2025)

7.2.3 Market Forecast (2026-2034)

7.3 Diabetes

7.3.1 Overview

7.3.2 Historical and Current Market Trends (2020-2025)

7.3.3 Market Forecast (2026-2034)

7.4 Oncology

7.4.1 Overview

7.4.2 Historical and Current Market Trends (2020-2025)

7.4.3 Market Forecast (2026-2034)

7.5 Growth Deficiency

7.5.1 Overview

7.5.2 Historical and Current Market Trends (2020-2025)

7.5.3 Market Forecast (2026-2034)

7.6 Female Infertility

7.6.1 Overview

7.6.2 Historical and Current Market Trends (2020-2025)

7.6.3 Market Forecast (2026-2034)

7.7 Others

7.7.1 Historical and Current Market Trends (2020-2025)

7.7.2 Market Forecast (2026-2034)

8 TURKEY BIOSIMILAR MARKET - BREAKUP BY MANUFACTURING TYPE

8.1 In-house Manufacturing

- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
- 8.2 Contract Manufacturing
 - 8.2.1 Overview
 - 8.2.2 Historical and Current Market Trends (2020-2025)
 - 8.2.3 Market Forecast (2026-2034)

9 TURKEY BIOSIMILAR MARKET – BREAKUP BY REGION

- 9.1 Marmara
 - 9.1.1 Overview
 - 9.1.2 Historical and Current Market Trends (2020-2025)
 - 9.1.3 Market Breakup by Molecule
 - 9.1.4 Market Breakup by Indication
 - 9.1.5 Market Breakup by Manufacturing Type
 - 9.1.6 Key Players
 - 9.1.7 Market Forecast (2026-2034)
- 9.2 Central Anatolia
 - 9.2.1 Overview
 - 9.2.2 Historical and Current Market Trends (2020-2025)
 - 9.2.3 Market Breakup by Molecule
 - 9.2.4 Market Breakup by Indication
 - 9.2.5 Market Breakup by Manufacturing Type
 - 9.2.6 Key Players
 - 9.2.7 Market Forecast (2026-2034)
- 9.3 Mediterranean
 - 9.3.1 Overview
 - 9.3.2 Historical and Current Market Trends (2020-2025)
 - 9.3.3 Market Breakup by Molecule
 - 9.3.4 Market Breakup by Indication
 - 9.3.5 Market Breakup by Manufacturing Type
 - 9.3.6 Key Players
 - 9.3.7 Market Forecast (2026-2034)
- 9.4 Aegean
 - 9.4.1 Overview
 - 9.4.2 Historical and Current Market Trends (2020-2025)
 - 9.4.3 Market Breakup by Molecule
 - 9.4.4 Market Breakup by Indication

9.4.5 Market Breakup by Manufacturing Type

9.4.6 Key Players

9.4.7 Market Forecast (2026-2034)

9.5 Southeastern Anatolia

9.5.1 Overview

9.5.2 Historical and Current Market Trends (2020-2025)

9.5.3 Market Breakup by Molecule

9.5.4 Market Breakup by Indication

9.5.5 Market Breakup by Manufacturing Type

9.5.6 Key Players

9.5.7 Market Forecast (2026-2034)

9.6 Black Sea

9.6.1 Overview

9.6.2 Historical and Current Market Trends (2020-2025)

9.6.3 Market Breakup by Molecule

9.6.4 Market Breakup by Indication

9.6.5 Market Breakup by Manufacturing Type

9.6.6 Key Players

9.6.7 Market Forecast (2026-2034)

9.7 Eastern Anatolia

9.7.1 Overview

9.7.2 Historical and Current Market Trends (2020-2025)

9.7.3 Market Breakup by Molecule

9.7.4 Market Breakup by Indication

9.7.5 Market Breakup by Manufacturing Type

9.7.6 Key Players

9.7.7 Market Forecast (2026-2034)

10 TURKEY BIOSIMILAR MARKET – COMPETITIVE LANDSCAPE

10.1 Overview

10.2 Market Structure

10.3 Market Player Positioning

10.4 Top Winning Strategies

10.5 Competitive Dashboard

10.6 Company Evaluation Quadrant

11 PROFILES OF KEY PLAYERS

11.1 Company A

11.1.1 Business Overview

11.1.2 Products Offered

11.1.3 Business Strategies

11.1.4 SWOT Analysis

11.1.5 Major News and Events

11.2 Company B

11.2.1 Business Overview

11.2.2 Products Offered

11.2.3 Business Strategies

11.2.4 SWOT Analysis

11.2.5 Major News and Events

11.3 Company C

11.3.1 Business Overview

11.3.2 Products Offered

11.3.3 Business Strategies

11.3.4 SWOT Analysis

11.3.5 Major News and Events

11.4 Company D

11.4.1 Business Overview

11.4.2 Products Offered

11.4.3 Business Strategies

11.4.4 SWOT Analysis

11.4.5 Major News and Events

11.5 Company E

11.5.1 Business Overview

11.5.2 Products Offered

11.5.3 Business Strategies

11.5.4 SWOT Analysis

11.5.5 Major News and Events

12 TURKEY BIOSIMILAR MARKET - INDUSTRY ANALYSIS

12.1 Drivers, Restraints, and Opportunities

12.1.1 Overview

12.1.2 Drivers

12.1.3 Restraints

12.1.4 Opportunities

12.2 Porters Five Forces Analysis

- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
- 12.3 Value Chain Analysis

13 APPENDIX

I would like to order

Product name: Turkey Biosimilar Market Size, Share, Trends and Forecast by Molecule, Indication, Manufacturing Type, and Region, 2026-2034

Product link: <https://marketpublishers.com/r/T1C48AF44594EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T1C48AF44594EN.html>